|Day Low/High||176.16 / 178.50|
|52 Wk Low/High||147.60 / 270.63|
The Dax rose following a strong performance from the automotive sector, but both London and Paris slumped.
Shire data presentations at AAAAI 2017 reinforce the efficacy, safety, and tolerability of CUVITRU for primary immunodeficiency patients
BioCryst's Hereditary angioedema drug-trial results not compelling.
Current drugs approved to prevent and reduce the frequency of HAE swelling attacks require injections, so BioCryst's once-daily pill has the potential to be more convenient.
Also up early Thursday: Bellicum and Novocure.
Shire posted full-year profits that were largely in-line with analysts' forecasts and said it could see double-digit percentage growth in 2017 earnings per share.
Shire presentations at EAHAD 2017 underscore the company's leadership in improving global standards of care
The charts of these and two other big stocks are flashing warning signs at investors.
The president-elect's words rattled the sector, though Amgen appears to be shrugging off his remarks.
U.S. stock futures and shares in London and Asia fall Thursday after Donald Trump offers few details on his policies during his first press conference since winning the U.S. election.
European health care and pharmaceutical company shares were hit hard Thursday after President-elect Donald Trump accused some firms of 'getting away with murder' in his Wednesday press conference.
U.S. Patent Office allows Mylan to go after half a dozen patents tied to Allergan's dry eye franchise Restasis.
The U.S. Food and Drug Administration turned down Amicus' request to seek accelerated approval for Galafold based on an existing kidney biomarker data.